Alzamend Neuro (NASDAQ:ALZN – Free Report) had its price target lowered by Ascendiant Capital Markets from $32.00 to $20.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.
Alzamend Neuro Trading Up 32.1 %
Shares of ALZN opened at $0.89 on Monday. Alzamend Neuro has a 52 week low of $0.64 and a 52 week high of $15.06. The stock has a fifty day moving average of $1.01 and a 200-day moving average of $1.35.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Sell-side analysts predict that Alzamend Neuro will post -1.68 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Further Reading
- Five stocks we like better than Alzamend Neuro
- What Are Trending Stocks? Trending Stocks Explained
- Can TikTok Stock Picks Really Make You Rich?
- Stock Market Sectors: What Are They and How Many Are There?
- The “Quality” Rotation: Back to Basics Investing
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.